16th World ADC London

With traditional ADCs now fulfilling their potential to reshape the standard of oncology care, the bioconjugate community is doubling down on differentiation to ensure the next wave of ADCs delivers meaningful impact for patients in need.

Returning as Europe’s longest-standing and definitive ADC forum, the 16th World ADC London is the week for anyone working in or looking to learn about bioconjugates. Leverage cutting-edge R&D, development strategy, and unparalleled networking opportunities to harness ADC innovation and maximise the therapeutic index of your ADCs.

With five streams of end-to-end content spanning discovery, preclinical and translational research, clinical lessons, process and analytical development, and manufacturing and supply chain, the 2026 agenda has been infused with trailblazing design, development, and production innovations to overcome patient resistance mechanisms and advance ADCs to earlier-line oncology treatments.

Brand-New 2026 Content Highlights

• Global ADC Speaker Faculty from Europe, North America & Asia
  As the leading forum for the European ADC community, the 2026 faculty brings together over 110 global experts, offering an international perspective to drive forward-thinking ADC innovation.
• Differentiated ADC Payload & Design Content Front and Centre
  Attend sessions on novel cytotoxic and non-cytotoxic payloads, dual payload conjugates, bispecific and biparatopic ADCs, and non-antibody conjugates — all designed to overcome patient resistance and move ADCs into earlier-line patient therapies.
• First-Time Presenting Companies
  Committed to showcasing fresh perspectives on ADC development, don’t miss first-time presenters including Adcoris Biopharma, ALX Oncology, Helix Biopharma, Radiance Biopharma, and Salubris Bio.
• New Regulator, Clinician & Investor Representation
  Expanding the speaker ecosystem, hear from the Paul Ehrlich Institute on ADC regulatory CMC, Paolo Tarantino on the power of ADC combinations, and diverse investor viewpoints on the ADC Licensing, Investment & Partnering Panel Session.

Uniting 800+ senior European ADC decision-makers across biopharma, clinical practice, service provision, investment, and regulation, World ADC London is proud to bring the community together to kick off 2026 and shape the future of ADC development.

Don’t miss the trailblazing innovations driving ADCs to earlier-line oncology treatments and transforming patient outcomes.

View the newly released 2026 programme here: https://ter.li/h0pjd0